Active Clinical Trials
Clinical trials are at the heart of our work to bring innovative medicines to people with a particular disease or condition. Learn more about the active studies conducted by Novartis including opportunities to get involved.
- Sort by Sort ascending
- Study title
- Condition
- Phase
- Location
- NCT ID
| Study title | Condition | Phase | Location | NCT ID |
|---|---|---|---|---|
A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis |
Diffuse Cutaneous Systemic Sclerosis | Phase2 | Argentina Austria Belgium Brazil China Colombia France Germany Greece Hungary India Italy Japan Malaysia Mexico Poland Portugal South Korea Spain Taiwan Thailand Turkey (Türkiye) United Kingdom United States Vietnam View all |
NCT06470048 |
Phase 2b Study to Investigate the Safety and Efficacy of TIN816 in Sepsis-associated Acute Kidney Injury (CLEAR-AKI) |
Acute Kidney Injury Due to Sepsis | Phase2 | Argentina Australia Austria Belgium Brazil Canada China France Germany Hungary India Italy Japan South Africa Spain Thailand United Kingdom United States View all |
NCT05996835 |
Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension). |
Systemic Lupus Erythematosus | Phase3 | Argentina Australia Brazil Bulgaria Canada Chile China Colombia Czechia France Germany Guatemala Hungary India Israel Italy Japan Malaysia Mexico Poland Portugal Romania South Africa South Korea Spain Taiwan Thailand United States View all |
NCT06133972 |
Asciminib Roll-over Study |
Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive | Phase4 | Argentina Austria Brazil Bulgaria Canada China Czechia France Germany Italy Malaysia Mexico Oman Poland Portugal Romania Russia South Korea Spain Turkey (Türkiye) United Kingdom United States Vietnam View all |
NCT04877522 |
Iptacopan in Patients With ANCA Associated Vasculitis |
Anti-Neutrophil Cytoplasm Antibodies (ANCA) Associated Vasculitis | Phase2 | Argentina Australia Austria Belgium Canada China Czechia Denmark France Germany Hungary Netherlands Spain Turkey (Türkiye) United Kingdom United States View all |
NCT06388941 |
A Study of Efficacy and Safety of Ianalumab in Previously Treated Patients With Warm Autoimmune Hemolytic Anemia |
Warm Autoimmune Hemolytic Anemia (wAIHA) | Phase3 | Argentina Australia China Germany Italy United Kingdom United States View all |
NCT05648968 |
Open-label, Long-term Safety Study of Secukinumab in Polymyalgia Rheumatica (PMR) |
Polymyalgia Rheumatica | Phase3 | Argentina Australia Belgium Colombia Czechia Denmark France Germany Hungary Israel Italy Japan Mexico Netherlands Poland South Africa Spain United Kingdom United States View all |
NCT06331312 |
Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1) |
Systemic Lupus Erythematosus | Phase3 | Argentina Brazil Bulgaria Canada China Colombia Czechia Guatemala Hungary Israel Japan Poland Portugal Singapore Slovakia South Africa Spain Thailand Turkey (Türkiye) United States View all |
NCT05639114 |
An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC. |
Oligometastatic Prostate Cancer (OMPC) | Phase3 | Argentina Australia Belgium Brazil Canada China Czechia France Germany Greece Hungary Israel Italy Japan Malaysia Mexico Netherlands Puerto Rico Singapore Slovakia Spain Switzerland Taiwan United Kingdom United States View all |
NCT05939414 |
Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2) |
Systemic Lupus Erythematosus | Phase3 | Argentina Australia Chile Colombia France Germany India Italy Malaysia Mexico Romania South Korea Taiwan United Kingdom United States View all |
NCT05624749 |